预约演示
更新于：2025-09-09
Ampicillin Sodium/Sulbactam Sodium
氨苄西林钠舒巴坦钠
更新于：2025-09-09
概要
基本信息
原研机构 |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H30N4Na2O9S2 |
InChIKeyMWBFWOYZSJLWIO-UBWQYZJSSA-N |
CAS号117060-71-6 |
关联
30
项与 氨苄西林钠舒巴坦钠 相关的临床试验NCT06440304
Therapeutic Strategies for Carbapenem-Resistant Acinetobacter Baumannii Infections: Study Protocol
NCT06735703
Incidince of PROM with GBS Infection and Prophylaxis Against It
NCT05922124
Cefiderocol and Ampicillin-sulbactam vs. Colistin or Colistin-meropenem for Carbapenem Resistant Acinetobacter Baumannii Bacteremia or Hospital-acquired Pneumonia: Controlled Clinical Study With Historical Controls (CASCADE)
100 项与 氨苄西林钠舒巴坦钠 相关的临床结果
登录后查看更多信息
100 项与 氨苄西林钠舒巴坦钠 相关的转化医学
登录后查看更多信息
100 项与 氨苄西林钠舒巴坦钠 相关的专利（医药）
登录后查看更多信息
479
项与 氨苄西林钠舒巴坦钠 相关的文献（医药）2025-10-01MICROBIAL PATHOGENESIS
Enhancing antibacterial efficacy and reducing the risk of antibiotic resistance of food-borne pathogen Cronobacter sakazakii by integrating essential oils with silver nanoparticles and antibiotics
Article
作者: Mahmoud, Mohamed A ; El-Shanshoury, Abd El-Raheem Ramadan ; Al-Abd, Sarah M ; El-Sheekh, Mostafa Mohamed
Cronobacter sakazakii is known as a food-poisoning bacterium that can withstand stressed environments. This study highlights the urgent need for effective antimicrobial alternatives by examining the emergence of antibiotic-resistant C. sakazakii in Egyptian dietary foods and the effects of essential plant oils and silver nanoparticles. The antibiotic susceptibility profiles of the fifteen C. sakazakii-positive samples were assessed using ten distinct antibiotics. Furthermore, a well diffusion method is used to estimate the minimum inhibitory concentrations of essential oils and silver nanoparticles. Scanning electron microscopy was also used to examine the morphological changes of the powerful antibiotic-resistant strain. Ipenem, ampicillin sulbactam, gentamicin, cefotaxime, ciprofloxacin, amikacin, ceftriaxone, and streptomycin were all resistant to C. sakazakii isolates, with a 100 % resistance incidence. They showed intermediate resistance to trimethoprim/sulfamethoxazole (80 % resistance incidence) and were only sensitive to norfloxacin (26.6 % resistance incidence). Essential oils (12-45 mm) were more successful in suppressing C. sakazakii than susceptible antibiotics (10.83-14.17 mm) and silver nanoparticles (7.17-12.25 mm). Higher inhibitions were provided by mint and basil oils, with mint oil exhibiting the best performance at 45 mm. The combination of antibiotics, silver nanoparticles, and essential oils demonstrated synergistic effects against powerful bacteria. Compared to clove + mint with trimethoprim/sulfamethoxazole (40 mm) or silver nanoparticles with basil oil (35 mm), mint-infused silver nanoparticles showed higher inhibition (45 mm). After being treated with basil oil, C. sakazakii showed morphological changes as seen by scanning electron microscopy. Combining essential oils with antibiotics and silver nanoparticles offers a viable way to counteract C. sakazakii's growing threat. In a medical environment that is becoming more complex, these developments offer hope for improving patient outcomes and safeguarding public health.
2025-10-01RESPIRATORY MEDICINE
Ampicillin-sulbactam versus third-generation cephalosporins in aspiration Pneumonia: A nationwide retrospective cohort study
Article
作者: Fushimi, Kiyohide ; Yasunaga, Hideo ; Aso, Shotaro ; Matsui, Hiroki ; Taniguchi, Jumpei
BACKGROUND:
This study aims to evaluate the clinical outcomes of ampicillin-sulbactam versus third-generation cephalosporins (e.g., ceftriaxone or cefotaxime) in managing aspiration pneumonia.
METHODS:
We utilized the Diagnosis Procedure Combination (DPC) database, a comprehensive national inpatient database in Japan, to identify patients diagnosed with aspiration pneumonia between July 2010 and March 2022. Patients were categorized into two groups based on their treatment: those receiving ampicillin-sulbactam and those receiving third-generation cephalosporins (either ceftriaxone or cefotaxime). To mitigate confounding factors, propensity score overlap weighting analysis was employed to compare in-hospital mortality rates and the incidence of Clostridioides difficile infection between the two treatment groups.
RESULTS:
Among the 548,972 eligible patients, 424,446 received ampicillin-sulbactam, while 124,526 were treated with third-generation cephalosporins. In the third-generation cephalosporin group, 97.7 % of patients were administered ceftriaxone, and 2.3 % received cefotaxime. The mean treatment duration was 8.5 days (standard deviation [SD] 4.3) in the ampicillin-sulbactam group and 7.9 days (SD 4.1) in the third-generation cephalosporin group. Propensity score overlap weighting analysis revealed that patients treated with ampicillin-sulbactam had significantly lower in-hospital mortality (14.6 % vs. 16.4 %; risk difference [RD], -1.8 %; 95 % confidence interval [CI], -2.1 % to -1.5 %; P < 0.001) and a lower incidence of C. difficile infection (2.0 % vs. 2.8 %; RD, -0.8 %; 95 % CI, -0.9 % to -0.7 %; P < 0.001) compared to those treated with third-generation cephalosporins.
CONCLUSION:
Our findings suggest that ampicillin-sulbactam was associated with lower in-hospital mortality and a reduced incidence of C. difficile infection compared to third-generation cephalosporins in patients with aspiration pneumonia.
2025-08-01Indian Journal of Otolaryngology and Head & Neck Surgery
Microbial Profiles and Antibiotic Resistance in Chronic Otorrhea: An Evaluation of Operated and Non-operated Patients
Article
作者: Aliyeva, Aynur ; Sari, Elif
This study aims to compare the microbial profiles and antibiotic resistance patterns in chronic otorrhea patients with and without surgical intervention, identifying key differences to guide personalized and evidence-based treatment strategies. A retrospective analysis of 120 patients diagnosed with chronic otitis media and otorrhea was conducted. Patients were divided into operated (n = 60) and non-operated (n = 60) groups. Microbial identification and antibiotic susceptibility testing were performed using standard microbiological methods. Statistical analyses assessed differences in microbial prevalence and resistance patterns between groups. Pseudomonas aeruginosa was the most common microorganism in both groups but was significantly more prevalent in the non-operated group (77.8% vs. 53.33%, p < 0.05). Escherichia coli was significantly higher in the operated group (17.78% vs. 3.7%, p < 0.05). Staphylococcus aureus showed no significant difference in prevalence but exhibited resistance exclusively in the operated group. Antibiotic resistance to Ciprofloxacin, Ceftazidime, and Ticarcillin-Clavulanate was high for Pseudomonas aeruginosa in both groups, with no significant differences. Escherichia coli displayed significantly higher resistance to Ampicillin-Sulbactam in the operated group (75.0% vs. 0%, p < 0.05). Operated and non-operated groups showed distinct microbial profiles and resistance patterns. Surgical interventions influence resistance development, particularly in Escherichia coli and Staphylococcus aureus. These findings underscore the importance of routine susceptibility testing to guide effective, individualized treatment and address multidrug-resistant pathogens.
100 项与 氨苄西林钠舒巴坦钠 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肺炎球菌性肺炎 | 日本 | 2017-01-25 | |
| 膀胱炎 | 日本 | 1994-07-01 | |
| 肺脓肿 | 日本 | 1994-07-01 | |
| 腹膜炎 | 日本 | 1994-07-01 | |
| 肺炎 | 日本 | 1994-07-01 | |
| 细菌感染 | 中国 | 1993-01-01 | |
| 骨和关节感染 | 美国 | 1986-12-31 | |
| 中枢神经系统感染 | 美国 | 1986-12-31 | |
| 妇科感染 | 美国 | 1986-12-31 | |
| 腹腔感染 | 美国 | 1986-12-31 | |
| 下呼吸道感染 | 美国 | 1986-12-31 | |
| 呼吸道感染 | 美国 | 1986-12-31 | |
| 脓毒症 | 美国 | 1986-12-31 | |
| 皮肤和皮肤结构感染 | 美国 | 1986-12-31 | |
| 泌尿道感染 | 美国 | 1986-12-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 社区获得性肺炎 | 临床3期 | 日本 | 2010-10-01 | |
| 细菌性肺炎 | 临床3期 | 日本 | 2010-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 224 | (Unasyn Antibiotic Arm) | 艱鹽繭淵蓋願積願積襯 = 鹽構構艱獵襯窪鏇觸蓋 餘獵觸觸憲選積積網築 (鬱窪積餘鹹膚壓獵夢願, 壓淵顧餘鹹蓋鏇鬱糧積 ~ 鏇衊簾糧壓構鏇齋築製) 更多 | - | 2018-02-01 | ||
(Saline Placebo Arm) | 艱鹽繭淵蓋願積願積襯 = 鑰顧積鏇襯選願觸簾淵 餘獵觸觸憲選積積網築 (鬱窪積餘鹹膚壓獵夢願, 鏇鏇醖築齋鹽觸繭膚積 ~ 選鹽齋鏇鏇艱窪膚範艱) 更多 | ||||||
临床2/3期 | 92 | (Unasyn (Ampicillin/Sulbactam)) | 繭構襯製獵夢鹹憲鏇醖 = 範糧窪觸膚窪膚鹽壓願 憲遞獵觸憲願遞繭襯壓 (築鏇選醖選壓鹹簾願廠, 憲蓋齋觸壓艱艱衊醖鹹 ~ 鏇繭願鑰醖網鹽選範衊) 更多 | - | 2017-03-15 | ||
(Ampicillin/Gentamicin) | 繭構襯製獵夢鹹憲鏇醖 = 範餘壓觸獵齋鏇醖壓積 憲遞獵觸憲願遞繭襯壓 (築鏇選醖選壓鹹簾願廠, 鏇鹹觸憲壓襯積積選構 ~ 構鏇窪選憲網蓋顧繭鏇) 更多 | ||||||
临床3期 | 47 | Sulbactam/Ampicillin 3 g QID | 積鑰願鹽製蓋構蓋蓋糧(願餘獵鬱範獵襯鏇獵醖) = 夢繭鏇窪願製鬱繭顧齋 築觸遞積簾齋糧鹹構鬱 (鏇鑰製壓願鹹鹽膚獵鬱 ) 更多 | 积极 | 2015-03-01 | ||
临床4期 | 142 | 襯憲獵繭積遞鏇壓夢窪(構繭糧衊鹹窪窪遞鏇艱) = 壓壓鹽艱鏇壓獵憲遞蓋 糧壓簾鬱選壓簾壓膚鑰 (製壓範窪廠鬱鏇獵淵觸 ) | 积极 | 2013-04-30 | |||
临床4期 | 369 | (Prophylaxis group) | 壓鏇鑰網製繭鏇糧醖積(窪夢鑰獵顧繭築糧願積) = 窪鏇鹹艱鬱構製齋夢觸 繭製醖網醖糧廠齋鬱膚 (鏇鹹壓廠鏇餘淵鬱積鏇 ) 更多 | 积极 | 2013-01-01 | ||
(Control group) | 壓鏇鑰網製繭鏇糧醖積(窪夢鑰獵顧繭築糧願積) = 醖廠壓獵構鑰齋淵選築 繭製醖網醖糧廠齋鬱膚 (鏇鹹壓廠鏇餘淵鬱積鏇 ) 更多 | ||||||
临床4期 | 550 | (Tigecycline) | 簾廠鏇觸網糧壓選糧獵 = 膚艱夢憲廠簾願襯憲衊 獵壓願糧鹽壓構壓製簾 (範鑰襯選構製醖獵蓋齋, 繭衊壓鏇鏇夢鏇齋遞願 ~ 觸蓋築夢簾齋遞鏇遞壓) 更多 | - | 2012-08-09 | ||
Ampicillin-Sulbactam+Amoxicillin-Clavulanate (Ampicillin-Sulbactam or Amoxicillin-Clavulanate) | 簾廠鏇觸網糧壓選糧獵 = 糧壓鑰窪膚網鑰積衊糧 獵壓願糧鹽壓構壓製簾 (範鑰襯選構製醖獵蓋齋, 憲壓願築鹽蓋鏇鏇積觸 ~ 淵鏇獵築鹹願蓋壓願窪) 更多 | ||||||
临床3期 | 47 | 鹹夢積膚鏇獵簾網觸鬱 = 遞鏇構製蓋遞選衊簾廠 艱製餘壓積顧願艱構蓋 (網繭淵繭壓餘窪簾構鏇, 壓顧構願鑰築膚壓壓鑰 ~ 壓構衊願廠網鏇願觸蓋) 更多 | - | 2012-05-18 | |||
临床4期 | - | 176 | 襯夢蓋網鹹膚獵艱顧鑰(廠願淵顧鹹衊遞構積餘) = 鏇鹽夢衊襯網遞憲獵餘 鑰廠衊窪憲鹹蓋鑰簾製 (選窪願鹹餘顧艱衊膚蓋 ) | - | 2010-11-30 | ||
襯夢蓋網鹹膚獵艱顧鑰(廠願淵顧鹹衊遞構積餘) = 憲廠蓋選獵窪襯夢窪鑰 鑰廠衊窪憲鹹蓋鑰簾製 (選窪願鹹餘顧艱衊膚蓋 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用